Address: Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark
Tel: +45 3326 8383
E-mail: info@bavarian-nordic.com
Website: http://bavarian-nordic.com
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. Bavarian Nordic works in partnership with Janssen, to develop MVA-BN vaccine technology for Ebola, HPV, HIV and Hepatitis B vaccines. In addition, Bavarian Nordic collaborates with Bristol-Myers Squibb, Roche and AstraZeneca to explore cancer immunotherapy candidates in combination with immune checkpoint inhibitors from their companies.
Bavarian Nordic’s 2012 financial results were very positive, with annual revenues doubling. How satisfied were you with this performance, and which factors drove this growth? We were extremely satisfied with…
Bavarian Nordic’s 2012 financial results were very positive, with annual revenues doubling. How satisfied were you with this performance, and which factors drove this growth? We were extremely satisfied with…
Bavarian Nordic’s 2012 financial results were very positive, with annual revenues doubling. How satisfied were you with this performance, and which factors drove this growth? We were extremely satisfied with…
In conversation at DIA Europe 2024 in Brussels, Lars Bo Nielsen lays out the digital transformation that the Danish Medicines Agency has undergone over the past three years and how…
After transitioning from a fledgling biotech to a mature commercial-stage company on the back of its first approval, Zealand Pharma was hit with the challenges of commercialisation and the disappointing…
LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has…
Ever since Novo Nordisk launched Wegovy two years ago, the company has struggled to meet the huge demand for its breakthrough weight loss drug and is yet to make it…
Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59,…
Denmark has long been a global frontrunner in medical research ethics and now boasts a more robust ethical infrastructure, spearheaded by a new body, The National Centre for Ethics. Head…
Henrik Brabrand, CEO of life science-focused executive search firm Albright Partners A/S, gives his expert insight into how to stand out above the crowd and get noticed by headhunters. …
Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed…
Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years,…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
The DKK 56bn (EUR 7.5bn) Danish medtech industry employs 15,200 workers, accounts for 7.4 percent of Danish business and industry’s total research investments, contributes to 1.4 percent of national GDP,…
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is…
See our Cookie Privacy Policy Here
